News and Articles

Local Cardiologists Evaluate Hypertension-Control Device in National Trial

2 comments

This article was written by Ann B. DeBellis of Birmingham Medical News. Uncontrolled hypertension is a dangerous condition that can lead to heart attack, stroke and even death. According to the Centers for Disease Control, more than 75 million Americans have high blood pressure and only half of them have the condition under control. Cardiologists

roxmedicalusLocal Cardiologists Evaluate Hypertension-Control Device in National Trial
read more

A New Way to Control High Blood Pressure and Cardiovascular Disease

5 comments

National Heart Month is dedicated to spreading knowledge behind Cardiovascular Disease (CVD) because awareness is key. When we know the telltale signs of CVD, we can help ourselves and our loved ones prevent the sometimes deadly side effects from these conditions and seek the correct treatment if needed. In our last blog post, we discussed

roxmedicalusA New Way to Control High Blood Pressure and Cardiovascular Disease
read more

The Heart of the Matter

No comments

February is “heart month” in many senses of the word. Right after the holidays, stores already began stocking up and selling heart candies, balloons, and cards all in preparation for Valentine’s Day. And why wouldn’t they? Love is something worthy of celebration! However, while those red and pink hearts are given to loved ones, they

roxmedicalusThe Heart of the Matter
read more

ROX Medical Inc. Announces Sustained Improvements in Patients with Uncontrolled Hypertension Treated with the ROX Coupler

No comments
CONTROL HTN 12-Month Data Published in Hypertension and to be presented at TCT 2017 SAN CLEMENTE, Calif., October 26, 2017 - ROX Medical Inc., a privately held medical device company pioneering an innovative interventional vascular therapy for uncontrolled hypertension, announced the publication of 12-month outcomes of the ROX CONTROL HTN study in the prestigious journal,
roxmedicalusROX Medical Inc. Announces Sustained Improvements in Patients with Uncontrolled Hypertension Treated with the ROX Coupler
read more

ROX Medical CONTROL HTN-2 Clinical Trial; First Procedure Performed

No comments
SAN CLEMENTE, Calif., October 3, 2017 - ROX Medical Inc. A privately held medical device company pioneering an innovative interventional vascular therapy for Uncontrolled Hypertension, announced today that the first patient was treated in the CONTROL HyperTeNsion (HTN)-2 clinical study, the Company's pivotal study to evaluate the safety and effectiveness of the ROX Coupler used
roxmedicalusROX Medical CONTROL HTN-2 Clinical Trial; First Procedure Performed
read more

ROX Medical presents positive data for CONTROL-HTN resistant hypertension trial

ROX Medical presented positive results from the CONTROL-HTN trial, an international multi-center, prospective, randomized, controlled, blinded endpoint study of the ROX Coupler for the treatment of arterial hypertension, at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in Washington, DC. The CONTROL-HTN trial, NCT01642498, evaluated the safety and efficacy of a percutaneous procedure creating a fixed

roxmedicalusROX Medical presents positive data for CONTROL-HTN resistant hypertension trial
read more

ROX Medical completes enrollment in CONTROL-HTN trial

ROX Medical announced it has completed enrollment for CONTROL-HTN trial, an international multi center, prospective, randomized, controlled, blinded endpoint trial of the ROX Coupler for the treatment of arterial hypertension. The CONTROL-HTN trial, NCT01642498, is evaluating the safety and efficacy of a percutaneous procedure creating a fixed connection between a central artery and vein in

roxmedicalusROX Medical completes enrollment in CONTROL-HTN trial
read more

ROX Medical adds 15th Clinical site, in Netherlands, to CONTROL-HTN randomized study

ROX Medical this week received confirmation of Ethics Committee approval at St. Antonius Hospital, Netherlands making it the 15th clinical center in the ROX CONTROL-HTN randomized study. St. Antonius will join centers across the UK, Belgium, Ireland, Germany, Poland and Greece. The CONTROL-HTN randomized study is a 100-patient trial to evaluate the ROX arterio-venous Coupler

roxmedicalusROX Medical adds 15th Clinical site, in Netherlands, to CONTROL-HTN randomized study
read more